# Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

> **NCT07227818** · PHASE3 · RECRUITING · sponsor: **Neurocrine Biosciences** · enrollment: 560 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** NBI-1117568
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07227818
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227818, "Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07227818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*